Show simple item record

dc.contributor.authorPotter, Danielle S
dc.contributor.authorGalvin, Melanie
dc.contributor.authorBrown, Stewart
dc.contributor.authorLallo, Alice
dc.contributor.authorHodgkinson, Cassandra L
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorMorrow, Christopher J
dc.contributor.authorDive, Caroline
dc.date.accessioned2016-06-24T12:16:04Z
dc.date.available2016-06-24T12:16:04Z
dc.date.issued2016-06
dc.identifier.citationInhibition of PI3K/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC. 2016, 15 (6):1248-60 Mol Cancer Theren
dc.identifier.issn1538-8514
dc.identifier.pmid27197306
dc.identifier.doi10.1158/1535-7163.MCT-15-0885
dc.identifier.urihttp://hdl.handle.net/10541/614579
dc.description.abstractMost small cell lung cancer (SCLC) patients are initially responsive to cytotoxic chemotherapy, but almost all undergo fatal relapse with progressive disease, highlighting an urgent need for improved therapies and better patient outcomes in this disease. The proapoptotic BH3 mimetic ABT-737 that targets BCL-2 family proteins demonstrated good single-agent efficacy in preclinical SCLC models. However, so far clinical trials of the BH3 mimetic Navitoclax have been disappointing. We previously demonstrated that inhibition of a PI3K/BMX cell survival signaling pathway sensitized colorectal cancer cells to ABT-737. Here, we show that SCLC cell lines, which express high levels of BMX, become sensitized to ABT-737 upon inhibition of PI3K in vitro, and this is dependent on inhibition of the PI3K-BMX-AKT/mTOR signaling pathway. Consistent with these cell line data, when combined with Navitoclax, PI3K inhibition suppressed tumor growth in both an established SCLC xenograft model and in a newly established circulating tumor cell-derived explant (CDX) model generated from a blood sample obtained at presentation from a chemorefractory SCLC patient. These data show for the first time that a PI3K/BMX signaling pathway plays a role in SCLC cell survival and that a BH3 mimetic plus PI3K inhibition causes prolonged tumor regression in a chemorefractory SCLC patient-derived model in vivo These data add to a body of evidence that this combination should move toward the clinic. Mol Cancer Ther; 15(6); 1248-60. ©2016 AACR.
dc.language.isoenen
dc.rightsArchived with thanks to Molecular cancer therapeuticsen
dc.titleInhibition of PI3K/BMX cell survival pathway sensitizes to BH3 mimetics in SCLC.en
dc.typeArticleen
dc.contributor.departmentClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchesteren
dc.identifier.journalMolecular Cancer Therapeuticsen
html.description.abstractMost small cell lung cancer (SCLC) patients are initially responsive to cytotoxic chemotherapy, but almost all undergo fatal relapse with progressive disease, highlighting an urgent need for improved therapies and better patient outcomes in this disease. The proapoptotic BH3 mimetic ABT-737 that targets BCL-2 family proteins demonstrated good single-agent efficacy in preclinical SCLC models. However, so far clinical trials of the BH3 mimetic Navitoclax have been disappointing. We previously demonstrated that inhibition of a PI3K/BMX cell survival signaling pathway sensitized colorectal cancer cells to ABT-737. Here, we show that SCLC cell lines, which express high levels of BMX, become sensitized to ABT-737 upon inhibition of PI3K in vitro, and this is dependent on inhibition of the PI3K-BMX-AKT/mTOR signaling pathway. Consistent with these cell line data, when combined with Navitoclax, PI3K inhibition suppressed tumor growth in both an established SCLC xenograft model and in a newly established circulating tumor cell-derived explant (CDX) model generated from a blood sample obtained at presentation from a chemorefractory SCLC patient. These data show for the first time that a PI3K/BMX signaling pathway plays a role in SCLC cell survival and that a BH3 mimetic plus PI3K inhibition causes prolonged tumor regression in a chemorefractory SCLC patient-derived model in vivo These data add to a body of evidence that this combination should move toward the clinic. Mol Cancer Ther; 15(6); 1248-60. ©2016 AACR.


This item appears in the following Collection(s)

Show simple item record